Novo's Ozempic (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro (tirzepatide), in real-world analysis at EASD (PRNewswire) - Sep 29, 2026 - "In the analysis, adults who escalated to semaglutide injection 2 mg were associated with a statistically significant 6% lower risk of major adverse cardiovascular events (MACE), including all-cause death, myocardial infarction (heart attack), and stroke, than those who switched to tirzepatide up to 15 mg (Adjusted HR 1.06; 95% CI 1.04-1.08; P=0.005)...At the 720-day follow up, fewer patients remained on semaglutide 1 mg (57.4%), reflecting continued treatment intensification over time, with 36.9% escalating to semaglutide 2 mg and 5.7% switching to tirzepatide...A subset of the study cohort evaluated patients with type 2 diabetes and more than one HbA1c and /or weight measurement at baseline and demonstrated consistent results (Adjusted HR, 1.07 [95% CI, 1.01-1.13], P<0.035).1 Safety outcomes were not assessed in this analysis."
Real-world • Retrospective data • Obesity
|